Table 4 Drug-related nonhematologic adverse events, that occurred in ≥ 10% of patients in any treatment arm, hematologic adverse events, and biochemical abnormalities, during the ENESTnd trial.
From: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
| Â | All grade (grade 3-4), % of patients | ||
|---|---|---|---|
Adverse event | Imatinib 400 mg QD | Nilotinib 300 mg BID | Nilotinib 400 mg BID |
Nonhematologic | Â | Â | Â |
   Nausea | 31 (0) | 11 (< 1) | 19 (1) |
   Diarrhea | 21 (1) | 8 (1) | 6 (0) |
   Vomiting | 14 (0) | 5 (0) | 9 (1) |
   Rash | 11 (1) | 31 (< 1) | 36 (3) |
   Pruritus | 5 (0) | 15 (< 1) | 13 (< 1) |
   Alopecia | 4 (0) | 8 (0) | 13 (0) |
   Headache | 8 (0) | 14 (1) | 21 (1) |
   Fatigue | 8 (< 1) | 11 (0) | 9 (1) |
   Muscle spasm | 24 (1) | 7 (0) | 6 (1) |
   Myalgia | 10 (0) | 10 (< 1) | 10 (0) |
   Peripheral edema | 14 (0) | 5 (0) | 5 (0) |
   Eyelid edema | 13 (< 1) | 1 (0) | 2 (< 1) |
   Periorbital edema | 12 (0) | < 1 (0) | 1 (0) |
Hematologic | Â | Â | Â |
   Neutropenia | 68 (20) | 43 (12) | 38 (10) |
   Thrombocytopenia | 56 (9) | 48 (10) | 49 (12) |
   Anemia | 47 (5) | 38 (3) | 38 (3) |
Biochemical abnormalities | Â | Â | Â |
   Elevated AST | 23 (1) | 40 (1) | 48 (3) |
   Elevated ALT | 20 (2) | 66 (4) | 73 (9) |
   Elevated bilirubin | 10 (< 1) | 53 (4) | 62 (8) |
   Elevated lipase | 11 (3) | 24 (6) | 29 (6) |
   Hyperglycemia | 20 (0) | 36 (6) | 41 (4) |
   Elevated creatinine | 13 (< 1) | 5 (0) | 5 (0) |
   Elevated amylase | 12 (1) | 15 (< 1) | 18 (1) |
   Elevated alkaline phosphatase | 33 (< 1) | 21 (0) | 27 (0) |
   Decreased phosphorus | 45 (8) | 32 (5) | 34 (5) |